HER3 Is a Determinant for Poor Prognosis in Melanoma

• Published in: Clinical cancer research Vol. 14; no. 16; pp. 5188 - 5197
• Main Authors: Reschke, Markus, Mihic-Probst, Daniela, van der Horst, Edward Htun, Knyazev, Pjotr, Wild, Peter J., Hutterer, Markus, Meyer, Stefanie, Dummer, Reinhard, Moch, Holger, Ullrich, Axel
• Format: Journal Article
• Language: English
• Published: Philadelphia, PA American Association for Cancer Research 15.08.2008
• Subjects: Adult; Aged; Aged, 80 and over; anti-HER3 monoclonal antibodies; Antineoplastic agents; Apoptosis - physiology; Biological and medical sciences; Biomarkers, Tumor - analysis; Blotting, Western; Cell Line, Tumor; Cell Movement - physiology; Cell Proliferation; Dermatology; Female; HER3; Humans; Immunohistochemistry; Kaplan-Meier Estimate; Male; Medical sciences; melanoma; Melanoma - metabolism; Melanoma - mortality; Melanoma - pathology; Middle Aged; Pharmacology. Drug treatments; PI3K-AKT signaling; Prognosis; receptor tyrosine kinases; Receptor, ErbB-3 - biosynthesis; Reverse Transcriptase Polymerase Chain Reaction; RNA Interference; Skin Neoplasms - metabolism; Skin Neoplasms - mortality; Skin Neoplasms - pathology; Tissue Array Analysis; Tumors of the skin and soft tissue. Premalignant lesions; Prognosis; Malignant tumor; Malignant melanoma; Cancer; Human Epidermal growth factor Receptor 3

Purpose: The epidermal growth factor receptor family member HER3 is overexpressed in diverse human cancers and has been associated with poor prognosis in breast, lung, and ovarian cancer. However, the relevance of HER3 with regard to its prognostic significance and function in primary melanoma and m...